EUVIMEDEUVIMED entdecken
Fallbericht

The double edge of erythropoietic modulation in thalassaemia

Paolo Ricchi iD

British Journal of Haematology · 2025

DOI: 10.1111/bjh.20142 ↗

Kurz gefasst

Fallbericht in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Paolo Ricchi. Beteiligte Einrichtung: Unità Operativa Semplice Dipartimentale Malattie Rare del Globulo Rosso, Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli", Napoli, Italy. Hauptthemen laut MEDLINE: beta-Thalassemia, Erythropoiesis, Recombinant Fusion Proteins, Thalassemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Luspatercept has emerged as a valuable therapeutic option for patients with transfusion‐dependent β‐thalassaemia, enabling significant reduction in transfusion requirements. In the report by Zaidel et al., a paradoxical clinical scenario is described in which treatment with luspatercept was associated with progressive splenomegaly, thrombocytopenia, increased haemolysis and a marked rise in reticulocytes and nucleated red blood cells, promptly reversible upon drug discontinuation. Luspatercept usually enhances late‐stage erythroid maturation, but, in rare cases like this, seems to trigger or exacerbate extramedullary haematopoiesis (EMH) and/or splenic sequestration. The report underscores the importance of close monitoring and a deeper understanding of individual susceptibility to optimize the safe use of luspatercept in thalassaemia. Further studies are needed to clarify the underlying mechanisms and to identify patients at risk for EMH‐related complications during luspatercept treatment. Commentary on: Zaidel et al. Acute splenomegaly, haemolysis, and thrombocytopenia following luspatercept initiation in a patient with transfusion‐dependent thalassaemia: A case report. Br J Haematol 2025; 206:1806‐1810.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-ThalassemiaErythropoiesisRecombinant Fusion ProteinsThalassemiaHumansHematopoiesis, ExtramedullaryHemolysisSplenomegalyThrombocytopeniaImmunoglobulin Fc FragmentsActivin Receptors, Type II

Stichwörter der Autor:innen

drugserythropoiesisthalassaemia

Substanzen

luspaterceptRecombinant Fusion ProteinsImmunoglobulin Fc FragmentsActivin Receptors, Type II

Autor:innen und Institutionen

  • Unità Operativa Semplice Dipartimentale Malattie Rare del Globulo Rosso, Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli", Napoli, Italy.

ORCID-Profile: Paolo Ricchi

Zitieren

APA

Ricchi, P. (2025). The double edge of erythropoietic modulation in thalassaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.20142

Vancouver

Ricchi P. The double edge of erythropoietic modulation in thalassaemia. British Journal of Haematology. 2025. doi:10.1111/bjh.20142

BibTeX
@article{Ricchi2025,
  author = {Ricchi, Paolo},
  title = {The double edge of erythropoietic modulation in thalassaemia},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.20142}
}
Kostenlos starten →